Drug Profile
Palonosetron intravenous - Exela Pharma Sciences
Alternative Names: Palonosetron hydrochloride intravenous - Exela Pharma SciencesLatest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Exela Pharma Sciences
- Class Antiemetics; Isoquinolines; Quinuclidines; Small molecules
- Mechanism of Action Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Chemotherapy-induced nausea and vomiting
Most Recent Events
- 31 Aug 2016 Chemical structure information added
- 22 Aug 2016 Registered for Chemotherapy induced nausea and vomiting (Prevention) in USA (IV)
- 22 Mar 2016 FDA issues tentative approval to palonosetron (0.125 mg/ml) injection for the prevention of Chemotherapy induced nausea and vomiting (In adults) in USA